title: Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.
abstract: Little progress has been made in the last three decades in the treatment of bladder cancer. Novel agents that are nontoxic and can improve the current standard of care of this disease are urgently needed. Curcumin, a component of Curcuma longa (also called turmeric), is one such agent that has been shown to suppress pathways linked to oncogenesis, including cell survival, proliferation, invasion and angiogenesis. We investigated whether curcumin has potential to improve the current therapy for bladder cancer, using an orthotopic mouse model. Curcumin potentiated the apoptotic effects of gemcitabine against human bladder cancer 253JBV cells in culture. Electrophoretic mobility shift assay revealed that curcumin also suppressed the gemcitabine-induced activation of the cell survival transcription factor NF-kappaB. In an orthotopic mouse model, bioluminescence imaging revealed that while curcumin alone significantly reduced the bladder tumor volume, maximum reduction was observed when curcumin was used in combination with gemcitabine (P<0.01 versus vehicle; P<0.01 versus gemcitabine alone). Curcumin also significantly decreased the proliferation marker Ki-67 and microvessel density (CD31) (P<0.01 versus vehicle; P<0.01 versus gemcitabine alone), but maximum reduction occurred when it was combined with gemcitabine (P<0.01 versus vehicle; P<0.01 versus gemcitabine alone). Curcumin abolished the constitutive activation of NF-kappaB in the tumor tissue; induced apoptosis, and decreased cyclin D1, VEGF, COX-2, c-myc and Bcl-2 expression in the bladder cancer tissue. Overall our results suggest that curcumin alone exhibits significant antitumor effects against human bladder cancer and it further potentiates the effects of gemictabine, possibly through the modulation of NF-kappaB signaling pathway.
authors.affiliation: Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, United States.
authors.forename: Sheeja T
authors.initials: ST
authors.lastname: Tharakan
authors.forename: Teruo
authors.initials: T
authors.lastname: Inamoto
authors.forename: Bokyung
authors.initials: B
authors.lastname: Sung
authors.forename: Bharat B
authors.initials: BB
authors.lastname: Aggarwal
authors.forename: Ashish M
authors.initials: AM
authors.lastname: Kamat
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001483:Base Sequence; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D003474:Curcumin / Q000494:pharmacology*; D017931:DNA Primers; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004357:Drug Synergism; D006801:Humans; D008954:Models, Biological; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000473:pathology*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D017931:DNA Primers; D003841:Deoxycytidine; D003474:Curcumin; D000093542:Gemcitabine
references.citation: Am J Trop Med Hyg. 1991 Oct;45(4):429-34
references.pmid: 1951851
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7490-8
references.pmid: 16243823
references.citation: BJU Int. 2007 Dec;100(6):1377-84
references.pmid: 17850390
references.citation: Mol Cancer Ther. 2004 Mar;3(3):279-90
references.pmid: 15026548
references.citation: Clin Cancer Res. 2003 Mar;9(3):955-60
references.pmid: 12631592
references.citation: Cancer Lett. 2008 Oct 8;269(2):199-225
references.pmid: 18479807
references.citation: J Biol Chem. 2004 Jun 18;279(25):26287-99
references.pmid: 15090542
references.citation: Mol Pharmacol. 2006 Jan;69(1):195-206
references.pmid: 16219905
references.citation: J Biol Chem. 2000 Apr 7;275(14):10405-12
references.pmid: 10744729
references.citation: Mol Cancer Ther. 2007 Mar;6(3):1022-30
references.pmid: 17363495
references.citation: J Urol. 1995 Oct;154(4):1532-8
references.pmid: 7658585
references.citation: Expert Opin Pharmacother. 2007 Dec;8(18):3251-6
references.pmid: 18035967
references.citation: Biochem Pharmacol. 2008 Feb 15;75(4):787-809
references.pmid: 17900536
references.citation: J Biol Chem. 1995 Oct 20;270(42):24995-5000
references.pmid: 7559628
references.citation: Exp Biol Med (Maywood). 2008 Jan;233(1):21-31
references.pmid: 18156302
references.citation: Cancer Res. 2007 Apr 15;67(8):3853-61
references.pmid: 17440100
references.citation: Cancer Res. 2005 Apr 1;65(7):2738-45
references.pmid: 15805273
references.citation: Cancer Cell. 2004 Sep;6(3):203-8
references.pmid: 15380510
references.citation: Haematologica. 2008 Oct;93(10):1544-9
references.pmid: 18641022
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4491-9
references.pmid: 18628464
references.citation: Methods Enzymol. 2000;319:585-602
references.pmid: 10907546
references.citation: Cancer Res. 2008 Jul 1;68(13):5345-54
references.pmid: 18593936
references.citation: J Clin Oncol. 2005 Jul 20;23(21):4602-8
references.pmid: 16034041
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387